Floatz Rating
C38/100
Confidence
Indicative
Sponsor
Zhejiang University
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05528354CT.gov Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Li-Fraumeni Syndrome
+10 more in the Li-Fraumeni Syndrome cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideMasonic Cancer Center, University of MinnesotaB
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitMasonic Cancer Center, University of MinnesotaCCC
- Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)The First Affiliated Hospital with Nanjing Medical UniversityCCC
- BusulfanumMasonic Cancer Center, University of MinnesotaCCC
- CatequentinibTianjin Medical University Cancer Institute and HospitalCCC
Citation
Floatz Terminal. Decitabine in Li-Fraumeni Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-li-fraumeni-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →